113 related articles for article (PubMed ID: 2592819)
21. [Increase in CDDP therapeutic index by lower concentration and longer infusion time--home chemotherapy for ovarian cancer].
Chen JT; Tatsuki Y; Hirai Y; Hasumi K
Gan To Kagaku Ryoho; 1993 Feb; 20(2):265-70. PubMed ID: 8434965
[TBL] [Abstract][Full Text] [Related]
22. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
23. [Relation of enzyme distribution in the kidney and increase pattern of urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma-GTP) activities following CDDP administration].
Takahashi T; Yoshida K; Nakame Y; Saitoh H
Hinyokika Kiyo; 1987 Oct; 33(10):1569-74. PubMed ID: 2895573
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM)].
Nishimura H; Yamada T; Hagio Y; Inoue T; Tsunawaki A; Yakushiji M; Kato T
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):938-43. PubMed ID: 6683483
[TBL] [Abstract][Full Text] [Related]
25. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
[TBL] [Abstract][Full Text] [Related]
26. Synergistic protective effect of
Abdel-Wahab WM; Moussa FI; Saad NA
Drug Des Devel Ther; 2017; 11():901-908. PubMed ID: 28356716
[TBL] [Abstract][Full Text] [Related]
27. [Study on gamma-GTP activity in urine and renal tissue of drug-induced nephrotoxicity in rats].
Furuta N; Nakada J
Nihon Hinyokika Gakkai Zasshi; 1993 Jul; 84(7):1197-205. PubMed ID: 8102655
[TBL] [Abstract][Full Text] [Related]
28. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
29. [Cisplatin administration for outpatients with short hydration of less than four hours].
Hata A; Katakami N; Masuda Y; Kaji R; Fujita S; Iwamori S; Horai A; Takatori K; Ose T; Kitajima N; Mifune Y; Fukae M
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1385-8. PubMed ID: 22996774
[TBL] [Abstract][Full Text] [Related]
30. [Hypomagnesemia following chemotherapy of disseminated testicular tumors].
Hida S; Nishimura K; Nishio Y; Okada Y; Okada K; Yoshida O
Hinyokika Kiyo; 1988 Jan; 34(1):52-60. PubMed ID: 2454015
[TBL] [Abstract][Full Text] [Related]
31. [Clinical study of combination chemotherapy with CDDP, ADM and CPM for ovarian cancer].
Kobayashi H; Maeda M; Hayata T; Kawashima Y
Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):829-36. PubMed ID: 3204307
[No Abstract] [Full Text] [Related]
32. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
33. [A clinical phase III trial of MR-20 in gynecologic nephrotoxicity of cisplatin--a comparative study in MR-20-treated and control patients on cyclical intermittent cisplatin treatment].
Ochiai K; Ikeda M; Kobayashi H; Nishimura H; Shibasaki T; Sakai O; Oh-hashi Y; Terashima Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):713-22. PubMed ID: 9571969
[TBL] [Abstract][Full Text] [Related]
34. [The effect of metoclopramide, dexamethasone and antihistamine in the prevention of PAC chemotherapy-induced emesis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Feb; 40(2):153-9. PubMed ID: 3361170
[TBL] [Abstract][Full Text] [Related]
35. [Study on urinary gamma-GTP activities as an indicator of cis-diamminedichloride platinum nephrotoxicity].
Takahashi T; Yoshida K; Nakame Y; Saitoh H
Hinyokika Kiyo; 1986 Jun; 32(6):789-94. PubMed ID: 2876605
[TBL] [Abstract][Full Text] [Related]
36. [CDDP-ACR treatment in patients with recurrent ovarian cancer with prior chemotherapy containing CDDP--a preliminary study of a 14-day continuous infusion of CDDP with ACR].
Chen JT; Hirai Y; Nakayama K; Shimizu Y; Yokosuka K; Teshima H; Hamada T; Fujimoto I; Yamauchi K; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1565-70. PubMed ID: 2584809
[TBL] [Abstract][Full Text] [Related]
37. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644
[TBL] [Abstract][Full Text] [Related]
38. [A clinical phase II trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Ogura T; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):89-96. PubMed ID: 9464334
[TBL] [Abstract][Full Text] [Related]
39. Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Vexler AM; Mou X; Gabizon AA; Gorodetsky R
Int J Cancer; 1995 Mar; 60(5):611-5. PubMed ID: 7532157
[TBL] [Abstract][Full Text] [Related]
40. [Low-dose CDDP and 5-FU for head and neck cancer patients].
Fujii M; Kanke M; Tomita T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
